Digital biomarkers of motor function as drug development tools in charcot-marie-tooth disease
Active Cooperative Agreement Awarded Last action
- Award ID
- U01FD009005
- Recipient
-
Biosensics LLC UEI C9MRZK4B7K39
- Awarding agency
-
FDA Office of Acquisition and Grant Services
Food and Drug Administration, Department of Health and Human Services
- Obligated
- $1,100,000
Award facts
- Assistance listing
- 93.103 Food and Drug Administration Research
- Completion date 8% complete
- Funding agency
- Center for Drug Evaluation and Research Food and Drug Administration, Department of Health and Human Services
- Place of performance
- Newtonville, MA 02458, USA
Award details come from USAspending.gov.
About this award
The Department of Health and Human Services Food and Drug Administration awarded Biosensics LLC a Cooperative Agreement (U01FD009005) totaling $1.1 million on September 23, 2026, under the Food and Drug Administration Research program (CFDA 93.103), which supports research, demonstration, and information dissemination activities. The source lists the Center for Drug Evaluation and Research as an alternate name for the funding agency.
The recipient will conduct an 18-month multi-site clinical validation study of wearable-sensor digital biomarkers for motor function in Charcot-Marie-Tooth disease type 1A (CMT1A), which accounts for over 50% of CMT cases worldwide. The work aims to establish these measures as drug development tools by assessing lower and upper limb function and physical activity at home. Elpida Therapeutics is a partner that will use the same sensors to collect exploratory outcomes on physical activity and hand function in its natural history study of CMT Type 4J and upcoming gene therapy clinical trials. The recipient also partners with the Hereditary Neuropathy Foundation on the use of its wearable technologies in CMT.
Dollars obligated are $1.1 million. The period of performance runs from the September 23, 2026 award date to an ultimate completion date of August 31, 2028. Place of performance is Newtonville, MA 02458, USA.
Description
- Abstract
- Charcot-marie-tooth (CMT) disease is a group of inherited disorders that cause nerve damage, primarily affecting the peripheral nerves, which are responsible for movement and sensation in the arms and legs. CMT is characterized by progressive muscle weakness and atrophy, particularly in the feet, legs, hands and arms. Clinical measures of CMT, largely based on quantitative variations on the neurological exam, have suboptimal sensitivity to change due to the slowly progressive nature of the disease and relevance to clinical meaning in patients' lives. More direct measures of physical activity, ambulation and hand function are not always assessed in the clinical setting, and rarely quantified. Such tasks require a consistent reproducible protocol and are highly susceptible to trial-to-trial variability, often serving as a poor reflection of natural ability and function. Biosensics has partnered with the hereditary neuropathy foundation to explore the use of its wearable-based digital health technologies in assessing lower and upper limb function in CMT. Our study with 47 adult participants with CMT established the feasibility and initial clinical validity of using wearable sensors for at-home monitoring of motor function and disease severity in CMT. In addition, elpida therapeutics has partnered with biosensics to use its wearable sensors to collect exploratory outcomes related to physical activity and hand function in its natural history study in CMT type 4J, a rare genetic subtype of CMT, and the upcoming gene therapy clinical trials. In this project, we will conduct an 18-month multi-site clinical validation study for the biomarkers of motor function in CMT1A, which accounts for over 50% of all CMT cases worldwide. CMT1A represents the most prevalent and clinically well-characterized demyelinating form of CMT and is the primary focus of nearly all current industry- sponsored therapeutic development programs, making IT an optimal initial population for digital motor biomarker development. The primary goal of the project is to qualify digital measures of motor function for CMT1A by working with the FDA innovative science and technology approaches for new drugs (ISTAND) program. Biosensics has already entered this pathway: the letter of intent for COU1 below was submitted to the ISTAND program in may 2026 and determined reviewable by FDA (DDT-IST-000073). This project generates the clinical validation evidence that will support its qualification plan. Context of use: COU1) wearable sensor-derived foot drop metrics as longitudinal outcome measures in adult CMT1A patients; COU2) wearable sensor-derived ambulation metrics passively acquired during activities of daily living as longitudinal outcome measures in adult CMT1A patients; COU3) wearable sensor-derived upper limb use metrics passively acquired during activities of daily living as longitudinal outcome measures in adult CMT1A patients. Moreover, as recommended by the FDA ISTAND program, we will interview participants at baseline, month 6, and month 18 using the technology acceptance model to examine perceived usefulness, perceived ease of use, and attitude toward use, and will ask participants whether they prefer at-home sensor monitoring or in-clinic strength testing.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Original award | $1,100,000 |
Quick answers
Who received award U01FD009005?
U01FD009005 was awarded to Biosensics LLC by FDA Office of Acquisition and Grant Services (Food and Drug Administration) on September 23, 2026.
How much is award U01FD009005 worth?
$1,100,000 has been obligated on U01FD009005.
Which agency awarded U01FD009005?
FDA Office of Acquisition and Grant Services (Food and Drug Administration) awarded U01FD009005, with funding from Center for Drug Evaluation and Research (Food and Drug Administration).
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award